Aurobindo Pharma receives 23 pdt approvals from MCC, South Africa

Aurobindo Pharma has received approvals from Medicines Control Council (MCC), South Africa for 23 registrations to manufacture and market in South Africa. With these approvals, Aurobindo has a total of 48 products representing 91 registrations approved by the MCC.
The approvals for 23 products includes Bavir 300 mg tablets, Deladex 200, 250, 400 mg DR capsules, Apafar 600 mg tablets, Colazid 150 and 300 mg tablets, Bindolam 10mg/ml orla solution, Bindopin 200 mg tablets, Auro-Ribavirin 200 mg tablets, Cylor 300 mg tablets, Zynovir 100 and 250 mg capsules, Emtricitabine 200 and 300 mg tablets and Auro-meloxicam 7.5 and 15 mg tablets. The company also received approval for two oral solution viz., Nysivir and Zynovir and one approval for oral suspension Bindopin. (Source: Pharmabiz)